Lucentis meets retinal vein occlusion endpoint

Genentech Inc. said Lucentis ranibizumab met the primary endpoint in the Phase III BRAVO trial to treat macular edema secondary to retinal vein occlusion. In the double-blind, U.S. trial in 397 patien...